Who is sponsoring NCT03148457?

NCT03148457 is sponsored by Insel Gruppe AG, University Hospital Bern.

What drugs are being tested in NCT03148457?

Interventions in NCT03148457: Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®), Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®).

What condition does NCT03148457 study?

NCT03148457 studies Ischaemic Stroke.

Is NCT03148457 still recruiting?

NCT03148457 is currently completed. Last updated 18 July 2023.

Last reviewed 2023-07-18 · How we verify

NCT03148457: ELAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

Completed NA Last updated 18 July 2023

What this trial tests

NA trial testing Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®) in Ischaemic Stroke in 2,013 participants. Completed in 24 May 2023.

Timeline

6 November 2017

Primary endpoint
21 December 2022

24 May 2023

Quick facts

Lead sponsor	Insel Gruppe AG, University Hospital Bern
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	2,013
Start date	6 November 2017
Primary completion	21 December 2022
Estimated completion	24 May 2023
Sites	98 locations across Italy, Finland, Japan, Greece, Slovakia, Belgium, Austria, Ireland

Drugs / interventions tested

Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)

Conditions studied

Ischaemic Stroke — all drugs for Ischaemic Stroke →

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

18 and older, any sex, with Ischaemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice. Direct oral anticoagulants (DOACs) are highly effective for secondary stroke prevention in these patients, but DOACs were never initiated \<7 days after stroke onset in recent trials. The ELAN trial will determine the net benefit of early versus late initiation of DOACs in patients with acute ischaemic stroke related to AF. The main objective is to estimate the net benefit of early versus late initiation of DOACs in patients with acute ischaemic stroke related to AF. The secondary objectives are to assess all vascular events and all-cause mortality after early initiation of DOACs in patients with acute ischaemic stroke related to AF compared to late initiation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Steffel J, Collins R, Antz M, Cornu P, et al · · 2021 · cited 670× · PMID 33895845 · DOI 10.1093/europace/euab065
Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation.
Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, et al · · 2019 · cited 162× · PMID 30415934 · DOI 10.1016/s1474-4422(18)30356-9
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.
Fischer U, Koga M, Strbian D, Branca M, et al · · 2023 · cited 156× · PMID 37222476 · DOI 10.1056/nejmoa2303048
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.
Klijn CJ, Paciaroni M, Berge E, Korompoki E, et al · · 2019 · cited 135× · PMID 31984228 · DOI 10.1177/2396987319841187
Blood Biomarkers for Stroke Diagnosis and Management.
Kamtchum-Tatuene J, Jickling GC. · · 2019 · cited 128× · PMID 30830566 · DOI 10.1007/s12017-019-08530-0
Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.
Oldgren J, Åsberg S, Hijazi Z, Wester P, et al · · 2022 · cited 108× · PMID 36065821 · DOI 10.1161/circulationaha.122.060666
Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.
Seiffge DJ, Paciaroni M, Wilson D, Koga M, et al · · 2019 · cited 81× · PMID 30980560 · DOI 10.1002/ana.25489
Overview of Acute Ischemic Stroke Evaluation and Management.
Hasan TF, Hasan H, Kelley RE. · · 2021 · cited 66× · PMID 34680603 · DOI 10.3390/biomedicines9101486

Verify or expand the search:

Other recruiting trials for Ischaemic Stroke

Currently open trials in the same condition.

NCT07197996 — The RETRAIN Trial Phase 2 · NA · recruiting
NCT06987643 — A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke · Phase 2 · recruiting
NCT06940635 — Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stro · NA · recruiting
NCT05922540 — a Cohort Study of Ischemic Cerebrovascular Disease · recruiting

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03148457 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
Last refreshed: 18 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03148457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing